![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Teva to Receive $700 Million After Agreement With Allergan
Teva to Receive $700 Million After Agreement With Allergan
![Teva.gif](https://www.fdanews.com/ext/resources/test/Drug-Images2/Teva.gif?t=1579040955&width=430)
February 6, 2018
Allergan has agreed to pay Teva a one-time $700 million payment to settle a dispute over working capital that was transferred between the companies when Teva acquired Allergan’s generics unit for $40.5 billion in 2016.
“The company expects to use this cash payment for repayment of a portion of its term loan debt,” Teva stated.
The settlement comes as a relief to the Israeli company, which has been plagued with debt problems since the deal. Teva, the world’s largest manufacturer of generics, recently made moves to raise $5 billion in securities and announced major reform plans that will eliminate thousands of positions and close or consolidate certain facilities.
Upcoming Events
-
21Oct